Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1183-1187

  Usery, Justin B ^a,b   Self, Timothy H ^b   Muthiah, Muthiah P ^c   Finch, Christopher K ^a,b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

5 lipoxygenase inhibitor; Chronic obstructive pulmonary disease; COPD; Leukotriene antagonist; Leukotriene modifier

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE 1,1 DIOXIDE; CORTICOSTEROID; ETALOCIB; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LY 29311; MK 866; MONTELUKAST; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; PREDNISONE; SB 201146; UNCLASSIFIED DRUG;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; HUMAN; LUNG FUNCTION; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 51849112807     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1183     Document Type: Review

References (22)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343(4):269-80.
2. Rabe KF, Hurd S, Anzueto A, et al, for the Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
3. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(5 pt 2):S72-9.
4. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002;122(1):289-94.
5. Lee E, Lindo T, Jackson N, et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999;160(6):2079-85.
6. Roche N. Recent changes: pulmonary medicine. BMJ 1999;318(7177):171-6.
7. 4 receptors in COPD. Chest 2006;129(6):1523-30.
8. 4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005;127(5):1553-9.
9. Montuschi P, Kharitonov SA, Ciavattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58(7):585-8.
10. 4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58(4):294-8.
11. 4. Eur Respir J 2000;15(2):274-80.
12. 4 levels in patients with obstructive pulmonary disease. Chest 1991;99(2):289-91.
13. Nannini LJ, Flores DM. Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2003;16(5):307-11.
14. 1-receptor antagonist. Pulm Pharmacol Ther 2000;13(6):301-5.
15. Kerstjens HA, Groen HJ, van Der Bij W. Recent advances: respiratory medicine. BMJ 2001;323(7325):1349-53.
16. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002;121(suppl 5):197-200S.
17. Mitsunobu F, Mifune T, Hosaki Y. Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2001;107(3):492-8.
18. 4. Chest 2003;123(4):1240-7.
19. Rubinstein I, Kumar B, Schriver C. Long-term montelukast therapy in moderate to severe COPD - a preliminary observation. Respir Med 2004;98(2):134-8.
20. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005;99(4):444-50.
21. Zuhlke IE, Kanniess F, Richter K. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J 2003;22(6):926-30.
22. Taube C, Holz O, Mucke M, Jorres RA, Magnussen H. Airway response to inhaled hypertonic saline in patients with moderate to severe COPD. Am J Respir Crit Care Med 2001;164:1810-15.